Frequent injections in the eye can cause infection, inflammation, and glaucoma. Akari is developing PAS-nomacopan with potential for 4 or fewer doses a year for the treatment geography atrophy (GA). Hear GA insights from Elias Reichel, M.D. at https://bit.ly/3OMMPkt $AKTX
